4.1 Therapeutic indications
Doxycycline has been found clinically effective in the treatment of a variety of
infections caused by susceptible strains of Gram-positive and Gram-negative bacteria
and certain other micro- organisms.
Respiratory tract infections
Pneumonia and other lower respiratory tract infections due to susceptible strains of
Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae and other organisms. Mycoplasma pneumoniae pneumonia. Treatment of chronic bronchitis, sinusitis.
Urinary tract infections
Infections caused by susceptible strains of Klebsiella species, Enterobacter species.
Escherichia coli, Streptococcus faecalis and other organisms.
Sexually transmitted diseases
Infections due to Chlamydia trachomatis including uncomplicated urethral, endocervical or rectal infections. Non-gonococcal urethritis caused by Ureaplasma urealyticum (T- mycoplasma).
Doxycycline is also indicated in chancroid, granuloma inguinale and lymphogranuloma venereum. Doxycycline is an alternative drug in the treatment of gonorrhoea and syphilis.
Acne vulgaris when antibiotic therapy is considered necessary.
Since Doxycycline is a member of the tetracycline group of antibiotics, it may be expected to be useful in the treatment of infections, which respond to other tetracyclines, such as:
Due to susceptible strains of gonococci, staphylococci and Haemophilus influenzae. Doxycycline Capsules are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence.
Rocky Mountain spotted fever, typhus group, Q fever, Coxiella endocarditis and tick fevers.
Psittacosis, cholera, meliodosis, leptospirosis, other infections due to susceptible strains of Yersinia species, Brucella species (in combination with Streptomycin), Clostridium species, Francisella tularensis and chloroquine-resistant falciparum malaria.
Doxycycline Capsules are indicated for prophylaxis in the following conditions: Scrub typhus, travellers' diarrhoea (enterotoxigenic Escherichia coli), leptospirosis.
Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC (www.medicines.org.uk/emc/). Medthority offers the whole library of SPC documents from eMC.
Medthority will not be held liable for explicit or implicit errors, or missing data.
Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).